Tucatinib for Metastatic HER2+ Breast Cancer and Brain Metastases: Patient Selection

Video

Ruta Rao, MD, discusses her rationale for treating metastatic HER2+ breast cancer with a tucatinib-containing regimen based on data from the HER2CLIMB trial.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Recent Videos
      Strategies for Monitoring and Managing T-DXd-Related Adverse Effects
      Strategies for Monitoring and Managing T-DXd-Related Adverse Effects
      The Evolving Role of T-DXd in HER2+ Metastatic Breast Cancer
      The Evolving Role of T-DXd in HER2+ Metastatic Breast Cancer
      Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
      Clinical Data May Support PARP Inhibition in Somatic BRCA-Mutant TNBC
      Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
      Considerations After Initial CDK4/6 Inhibition in HR+/HER2– Breast Cancer
      T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
      T-DXd May Be the Preferred ADC in HR+/HER2– Breast Cancer
      Optimizing Maintenance Therapy After First-Line Treatment in HER2+ Metastatic Breast Cancer
      Optimizing Maintenance Therapy After First-Line Treatment in HER2+ Metastatic Breast Cancer
      Current Treatment Approaches in HER2+ Metastatic Breast Cancer
      Current Treatment Approaches in HER2+ Metastatic Breast Cancer
      Complex ES-SCLC Case: Tarlatamab Management Through Toxicity to Clinical Benefit
      Complex ES-SCLC Case: Tarlatamab Management Through Toxicity to Clinical Benefit
      Seamless Transitions: Managing the Inpatient to Outpatient Care Continuum
      Seamless Transitions: Managing the Inpatient to Outpatient Care Continuum
      Future Research Priorities: Optimizing Tarlatamab Administration and Toxicity Management
      Future Research Priorities: Optimizing Tarlatamab Administration and Toxicity Management
      Related Content
      20 Impact of Ribociclib Dose Reduction on Efficacy in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast

      20 Impact of Ribociclib Dose Reduction on Efficacy in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast

      Radhika Appaya;Erika P. Hamilton, MD;Thomas Decker;Hope S. Rugo, MD;Maria Fernandez Abad;Kevin Kalinsky, MD, MS;Qiang Liu;Mariya Rozenblit, MD;Barbara Radecka;Seock-Ah Im;Frances Visco;Alejandro Perez;Yogesh Chattar;Murat Akdere;Vaidyanathan Ganapathy;Sorcha Waters;Joyce O’Shaughnessy, MD
      June 27th 2025
      Article

      Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

      Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

      Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
      April 21st 2025
      Podcast

      Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

      Survivors of breast cancer face increased cardiovascular risks due to treatment-related cardiotoxicity, and understanding these risks is crucial for effective management and prevention.

      Cardio-Oncology Considerations for Breast Cancer: Risk Stratification, Monitoring, and Treatment

      ONCOLOGY Staff
      June 26th 2025
      Article

      Survivors of breast cancer face increased cardiovascular risks due to treatment-related cardiotoxicity, and understanding these risks is crucial for effective management and prevention.

      Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

      SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

      Paolo Tarantino, MD;Matteo Lambertini, MD
      January 13th 2025
      Podcast

      Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

      Retrospective analysis at SNMMI 2025 revealed α-FRT with 225AC-3BP-3940 was well tolerated and elicited responses in pretreated metastatic breast cancer.

      225AC-3BP-3940 Is Safe, Shows Activity in Heavily Pretreated Advanced Breast Cancer

      Gina Mauro
      June 24th 2025
      Article

      Retrospective analysis at SNMMI 2025 revealed α-FRT with 225AC-3BP-3940 was well tolerated and elicited responses in pretreated metastatic breast cancer.

      23 Clinical Outcomes in Patients With HR+/HER2− Early Breast Cancer By Prior Systemic Treatment: A Subgroup Analysis of the NATALEE Trial

      23 Clinical Outcomes in Patients With HR+/HER2− Early Breast Cancer By Prior Systemic Treatment: A Subgroup Analysis of the NATALEE Trial

      Radhika Appaya;Nicholas McAndrew;Stephen Chia;Fabio Puglisi;Aditya Bardia, MD, MPH;Yann Izarzugaza;Christian Schem, MD;Binghe Xu;Fanny Le Du;Priyanka Sharma, MD;Karen Afenjar;Murat Akdere;Juan Pablo Zarate;Yogesh Chattar;Peter A. Fasching
      June 23rd 2025
      Article